Intrauterine Device – Levo­nor­gestrel 52 mg [Design Issues]

posted by Relaxation  – Germany, 2021-06-30 17:22 (327 d 05:56 ago) – Posting: # 22445
Views: 682

Dear Marianna.

Interesting question. Although I'd say its possible in principle (but have no experience myself with this specific approach for a long-term contraceptive), I would say that some more information is required.

Like is the CV you mentioned taken from a clinical trial at least similar to the intended investigation? And from a similar evaluation (point estimates and CI available, ANOVA on logarithmized values)? Or from a descriptive statistic and calculated as mean/standard deviation?
I think a link to the report of the phase II would be the best approach here, if something like that is available.

I may also say, that, given that the trial will take at least 12 months and likely hundreds of subjects in each arm will be required, it may be wise to get a biostatistician involved into the trial who can thoroughly check the available data, whether these fit.

Best regards,

Complete thread:

UA Flag
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Monday 23:18 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz